PuSH - Publication Server of Helmholtz Zentrum München

17 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Angenendt, L.* et al.: The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia, accepted (2019)
2.
Fröhlich, F. et al.: Efficient parameter estimation enables the prediction of drug response using a mechanistic pan-cancer pathway model. Cell Syst. 7, 567-579 (2018)
3.
Braenne, I.* et al.: Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. PLoS ONE 12:e0182999 (2017)
4.
Braenne, I.* et al.: A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Sci. Rep. 7:10252 (2017)
5.
Saleheen, D.* et al.: Loss of cardioprotective effects at the ADAMTS7 locus as a result of gene-smoking interactions. Circulation 135, 2336-2353 (2017)
6.
Webb, T.R.* et al.: Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease. J. Am. Coll. Cardiol. 69, 823-836 (2017)
7.
Wierer, M.* et al.: Compartment-resolved proteomic analysis of mouse aorta during atherosclerotic plaque formation reveals osteoclast-specific protein expression. Mol. Cell. Proteomics 17, 321-334 (2017)
8.
Aherrahrou, Z* et al.: Knock-out of nexilin in mice leads to dilated cardiomyopathy and endomyocardial fibroelastosis. Basic Res. Cardiol. 111:6 (2016)
9.
Braenne, I.* et al.: Pleiotropic molecular targets of coxibs reveals novel genomic loci conferring coronary artery disease risk. Atherosclerosis 252, E252-E253 (2016)
10.
Fröhlich, F. et al.: Large-scale modeling of cancer signaling: Mechanistic modeling meets Big Data. Eur. J. Cancer 68, S44-S44 (2016)
11.
Stitziel, N.O.* et al.: Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N. Engl. J. Med. 374, 1134-1144 (2016)
12.
Stitziel, N.O.* et al.: Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease (vol 374, pg 1134, 2016). N. Engl. J. Med. 374, 1898-1898 (2016)
13.
Interleukin 1 Genetics Consortium et al.: Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: A mendelian randomisation analysis. Lancet Diabet. Endocrinol. 3, 243-253 (2015)
14.
Brænne, I.* et al.: Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur. J. Hum. Genet. 24, 191-197 (2015)
15.
Kessler, T.* et al.: ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling via cleavage of thrombospondin-1. Circulation 131, 1191-1201 (2015)
16.
Stitziel, N.O.* et al.: Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 371, 2072-2082 (2014)
17.
Deloukas, P.* et al.: Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 45, 25-35 (2013)